|
Published by: Datamonitor
Published: Aug. 1, 2001 - 52 Pages
Table of Contents
DATAMONITOR HEALTHCARE
CONTACT DETAILS
EXECUTIVE SUMMARY
Datamonitor insight into the HIV Market
Key Metrics
INTRODUCTION
Report structure
ANALYSIS OF KEY Q2 DEVELOPMENTS
KEY HEADLINE - BMS acquires DuPont to expand its HIV market share and R&D
pipeline
COMPANY HEADLINES
GSK and Shionogi strategize a global development and commercializaton alliance
in HIV
Chiron licences its HIV-1 and HCV testing to Roche
Supplying workers with HIV therapy to maintain work-productivity -
DaimlerChrysler continues trend
RESEARCH AND DEVELOPMENT HEADLINES
Abbott to collaborate with Visible Genetics HIV-1 Genotyping
Joint HIV drug discovery program launched by the NCI and Panacos
CD8 T lymphocyte findings stimulate new research leads
GSK HIV vaccine success in monkeys
Remune passes the safety test for HIV patients and receives a boost in Thailand
Topical defence against HIV being targeted by Crompton and Biosyn
Promising results for SuperGen's anti-HIV agent
AZT and lamivudine prove potential of multiple treatment in reducing vertical
HIV transmission
Heat shock protein-based approach to HIV will be tested
Update on Gilead Sciences tenofovir shows promising results
DISEASE SPECIFIC HEADLINES
Morning After HIV therapy sparks debate
HIV resistance in the UK - a growing problem
Japan reports fall in HIV and AIDS cases
Worrying HIV trends revealed by CDC report
How bad is the news of drug-resistant HIV?
EMERGING MARKETS HEADLINES
Clashes with Kenyan Government over Pricing
Patent policies in Brazil make an impact
Centra's e-learning platform to be used for HIV education in emerging markets
Pfizer investigates HIV prophylaxis in Uganda
THE 1ST IAS CONFERENCE ON HIV PATHOGENESIS AND TREATMENT
Introduction
KEY FINDINGS
Tipranavir: Potential usage in PI-resistant patients
Atazanavir: 24-week report suggests it to be a safer PI
Abacavir: Is it really a viable candidate as a once-daily drug?
Norvir - potential use in salvage therapy
Resistant strains show trackable transmission patterns
Tenofovir DF and lopinavir: continued evidence of a low-resistance profile but
in different patient groups
Maybe NRTIs are to blame for lypodystrophy - not PIs.
Triple class HAART vs. standard HAART - the drug combinations of the future?
STIs could halve quantities taken in HIV therapies
The importance of adherence in patients with low CD4+ counts
Conclusions
2000 MARKET ANALYSIS
Market share by class
NRTIs
PIs
NNRTIs
Market share by country
Market share by company
FORECASTS 2001-2007
Drug class forecasts
Product forecasts
Immune based therapies and entry inhibitors
Drug combination forecasts
Conclusions
AbstractDatamonitor's HIV Quarterly Updates provide timely analysis of recent developments in this dynamic market. Each quarter, key events impacting the HIV market are identified, and insight is provided into their effect on future market developments. In addition, each of the HIV Quarterly Updates focuses on one or two 'hot' issues in the HIV market, providing you with actionable and future-focused conclusions and recommendations.
Get Full Details About This Report >>
|
